Aerosolized amikacin for treatment of pulmonary Mycobacterium avium infections: an observational case series

BACKGROUND: Current systemic therapy for nontuberculous mycobacterial pulmonary infection is limited by poor clinical response rates, drug toxicities and side effects. The addition of aerosolized amikacin to standard oral therapy for nontuberculous mycobacterial pulmonary infection may improve treat...

Descripción completa

Detalles Bibliográficos
Autores principales: Davis, Kala K, Kao, Peter N, Jacobs, Susan S, Ruoss, Stephen J
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2007
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1808062/
https://www.ncbi.nlm.nih.gov/pubmed/17319962
http://dx.doi.org/10.1186/1471-2466-7-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1808062/
https://www.ncbi.nlm.nih.gov/pubmed/17319962
http://dx.doi.org/10.1186/1471-2466-7-2

Ejemplares similares